Key statistics dashboard for Forte Biosciences, Inc. (FBRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Stock Data
| Price | $76.99 |
| Market Cap | $1.6B |
| Enterprise Value | $1.53B |
| Beta | 3.20 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -16.77 |
| Price / Book | 9.96 |
| P/S | 0.00 |
| EV/EBITDA | -17.71 |
| EV/Sales | 0.00 |
| EV/FCF | -21.21 |
| P/FCF | -21.90 |
| Earnings Yield | -4.80% |
| FCF Yield | -4.57% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -94.82% |
| Return on Assets | -42.74% |
| Return on Invested Capital | -48.53% |
| Return on Capital Employed | -48.53% |
Financial Health
| Current Ratio | 10.01 |
| Quick Ratio | 10.01 |
| Cash Ratio | 2.45 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.58 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 7.73 |
| Cash per share | 8.34 |
| FCF per share | -3.03 |
| Tangible Book Value per share | 7.73 |
| Dividend per share | 0.00 |
Related companies: ACTU · ALEC · APLT · CRBP · CRDF · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of FBRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks